文献速递神经肿瘤

阻断LINC00152通过miR-612/AKT2/NF-κB通路损害间充质表型抑制胶质母细胞瘤恶性进展

Blocking LINC00152 suppresses glioblastoma malignancy by impairing mesenchymal phenotype through the miR-612/AKT2/NF-κB pathway.
PubMed 文献 · J Neurooncol · 2018-07-24

研究利用公共数据库生物信息学方法筛选出长链非编码RNA LINC00152,并在胶质母细胞瘤中探究其临床价值与潜在机制。结果显示LINC00152与胶质瘤WHO分级及不良预后密切相关,阻断后可在体外和体内抑制肿瘤生长与侵袭,并通过miR-612依赖的AKT2/NF-κB通路调控前神经-间充质转化。

要点

  • LINC00152与胶质瘤WHO分级及不良预后密切相关。
  • 阻断LINC00152可在体外和体内抑制肿瘤生长与侵袭。
  • LINC00152经miR-612依赖的AKT2/NF-κB通路调控前神经-间充质转化。

核心结论

  • LINC00152作为肿瘤癌基因,通过LINC00152/miR-612/AKT2/NF-κB轴对胶质母细胞瘤患者具有预后价值。

研究设计与样本

  • 研究采用公共数据库的生物信息学方法筛选LINC00152并探究其临床价值与潜在机制,使用CCK-8、transwell实验、集落形成和伤口愈合实验探索其恶性行为,并采用PCR、western blot、免疫荧光、报告基因实验和裸鼠颅内肿瘤模型进一步验证调控机制。

主要发现

  • LINC00152与胶质瘤WHO分类及不良预后密切相关,并在胶质母细胞瘤患者中提示不良预后。
  • 阻断LINC00152后,体外和体内肿瘤生长与侵袭均被抑制。
  • LINC00152通过miR-612依赖的AKT2/NF-κB通路调控胶质母细胞瘤恶性进展和前神经-间充质转化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Glioblastoma, the most common and mortal primary brain tumor, accompanied with a dismal clinical outcome in adults. The oncogenic functions of long non-coding RNAs (lncRNAs) in glioblastoma have not been completely illuminated. In the present study, we aimed to investigate the potential role of lncRNA LINC00152 in glioblastoma. METHODS: We used bioinformatic method in public databases to select lncRNA LINC00152 and investigate its clinical value and potential mechanism in glioblastoma. CCK-8, transwell assay, colony formation and wound healing assays were used to explore the role of LINC00152 in glioblastoma malignant behaviors. PCR, western blot, immunofluorescence, reporter assays and nude mouse tumor intracranial model were employed to further verify the regulatory mechanism of LINC00152 in glioblastoma. RESULTS: LINC00152 was closely associated with glioma WHO classification and poor prognosis, and indicated a poor prognosis in glioblastoma patients. Tumor growth and invasion were suppressed both in vitro and vivo after LINC00152 was blocked. Moreover, LINC00152 modulated GBM malignant progression and proneural-mesenchymal transition through the miR-612 dependent AKT2/NF-κB pathway. CONCLUSIONS: LINC00152 acted as a tumor oncogene with prognostic value for patients with glioblastoma through LINC00152/miR-612/AKT2/NF-κB axis.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Cai J, Zhang J, Wu P, et al. Blocking LINC00152 suppresses glioblastoma malignancy by impairing mesenchymal phenotype through the miR-612/AKT2/NF-κB pathway. J Neurooncol. 2018. PMID: 30043319. doi:10.1007/s11060-018-2951-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。